Earlier this year, President Trump issued an executive order pledging “immediate steps to end global freeloading” and “aggressive action” to ensure drugmakers “offer American consumers the ...

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.

The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug ...

Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

Montana joins more than a dozen state governments so far this year that have taken steps to either introduce or enact similar ...

Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer ...

Honduran Elmer Rueda-Linares, 18, arrested entering the country illegally in June 2021, was promptly released -- on Mayorkas' ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

Medicare Part D premiums will increase next year, the Centers for Medicare & Medicaid Services (CMS) announced as the agency adjusts a Biden-era program. | The Trump administration is also modifying ...

The One Big Beautiful Bill Act ("OBBB") expands exemptions for orphan drugs from mandatory Medicare price negotiations and modifies their ...